Pfizer released full Phase 3 data showing its experimental mRNA influenza vaccine candidate delivered a 34.5% greater protective efficacy than a standard control vaccine in the trial cohort. The result broadens the clinical evidence that mRNA platforms can outperform traditional flu vaccines and supports regulatory filings and commercialization plans. The trial result gives Pfizer momentum to push mRNA beyond COVID into routine seasonal immunization and strengthens the case for platform expansion by other mRNA makers. Key questions remain about strain coverage, durability across seasons, and supply chain scale‑up if regulators approve the vaccine for routine use. Investors and competitors will watch how payers price mRNA flu shots versus incumbent vaccines and whether the efficacy margin translates into real‑world reductions in hospitalizations and severe outcomes.